SecSonar.com

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding Corp. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Tonix Pharmaceuticals Holding Corp. (TNXP) is a Biotechnology company based in US with a market capitalization of $198M. Revenue grew 29.9% year-over-year and free cash flow was negative at -$103.2M. This page tracks TNXP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 81 employees · IPO May 10, 2012

Valuation

Valuation & price

$15.74 · as of May 17, 2026 · -74.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.81

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$59.76$35.36$10.96Jul 25Dec 25Jun 26Jul 7, 25$35.44Jul 9, 25$38.36Jul 11, 25$40.87Jul 15, 25$44.20Jul 17, 25$47.19Jul 21, 25$45.10Jul 23, 25$45.52Jul 25, 25$49.73Jul 29, 25$42.63Jul 31, 25$37.68Aug 4, 25$44.64Aug 6, 25$45.62Aug 8, 25$46.49Aug 12, 25$59.76Aug 14, 25$59.58Aug 18, 25$40.07Aug 20, 25$36.05Aug 22, 25$37.98Aug 27, 25$32.18Aug 29, 25$29.63Sep 3, 25$27.70Sep 5, 25$26.54Sep 9, 25$25.82Sep 11, 25$31.21Sep 15, 25$27.75Sep 17, 25$27.71Sep 19, 25$26.00Sep 23, 25$25.29Sep 25, 25$24.00Sep 29, 25$24.76Oct 1, 25$23.95Oct 3, 25$24.00Oct 7, 25$23.00Oct 9, 25$22.54Oct 13, 25$20.06Oct 16, 25$18.81Oct 20, 25$19.84Oct 22, 25$18.88Oct 24, 25$19.49Oct 28, 25$19.49Oct 30, 25$18.06Nov 3, 25$18.76Nov 5, 25$18.12Nov 7, 25$17.00Nov 11, 25$17.53Nov 13, 25$16.15Nov 17, 25$16.81Nov 19, 25$16.72Nov 21, 25$16.10Nov 25, 25$14.08Nov 28, 25$15.97Dec 2, 25$15.52Dec 5, 25$19.64Dec 9, 25$19.60Dec 11, 25$19.63Dec 15, 25$18.86Dec 17, 25$17.99Dec 19, 25$17.09Dec 23, 25$16.78Dec 26, 25$16.26Dec 30, 25$15.82Jan 2, 26$16.55Jan 6, 26$15.36Jan 8, 26$15.17Jan 12, 26$15.77Jan 14, 26$16.90Jan 16, 26$17.14Jan 21, 26$18.17Jan 23, 26$18.32Jan 28, 26$18.29Jan 30, 26$17.24Feb 3, 26$17.16Feb 5, 26$14.95Feb 9, 26$16.25Feb 11, 26$15.86Feb 13, 26$15.14Feb 18, 26$15.08Feb 20, 26$14.04Feb 24, 26$14.29Feb 26, 26$14.43Mar 2, 26$13.98Mar 4, 26$13.98Mar 6, 26$13.45Mar 10, 26$14.17Mar 12, 26$13.41Mar 16, 26$13.56Mar 19, 26$15.77Mar 23, 26$16.08Mar 25, 26$15.00Mar 27, 26$12.88Mar 31, 26$13.75Apr 2, 26$13.90Apr 7, 26$13.07Apr 9, 26$13.00Apr 13, 26$12.98Apr 15, 26$14.34Apr 17, 26$13.98Apr 21, 26$13.51Apr 23, 26$12.49Apr 27, 26$12.84Apr 29, 26$12.40May 1, 26$13.60May 5, 26$13.50May 8, 26$14.09May 12, 26$13.28May 14, 26$14.09May 18, 26$14.26May 20, 26$14.50May 22, 26$12.77May 27, 26$12.15May 29, 26$12.33Jun 2, 26$11.72Jun 4, 26$11.88Jun 8, 26$11.71Jun 10, 26$10.96Jun 12, 26$11.35Jun 16, 26$11.63Jun 18, 26$12.01Jun 23, 26$11.96Jun 29, 26$12.81
$10.6552-week range$61.57
Loading valuation history…

Fundamentals

Key fundamentals

$198M

Market cap

29.9%

Revenue growth (YoY)

34.6%

Gross margin

-$103.2M

Free cash flow (USD)

-$206.3M

Net debt

Net cash position

276.0%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$7.8MFY 2024$10.1MFY 2025$13.1M
$0$13.1M

Free cash flow by year

2016 → 2025

FY 2016$-37.4MFY 2017$-19.1MFY 2018$-24.0MFY 2019$-26.7MFY 2020$-57.1MFY 2021$-110.9MFY 2022$-146.2MFY 2023$-109.9MFY 2024$-61.0MFY 2025$-103.2M
-$37.4M-$103.2M

Gross margin by year

2023 → 2025

FY 202339.0%FY 202423.1%FY 202534.6%
39.0%34.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventPhase 2 Study EnrollmentJun 29, 2026Filing
  • 8-K eventCommercial Coverage AgreementJun 8, 2026Filing
  • 8-K eventClinical Study PublicationMay 27, 2026Filing
  • 8-K eventNew Drug AnnouncementMay 15, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 7, 2026Filing
  • 8-K eventCommercial Payer Coverage SecuredMay 6, 2026Filing
  • 8-K eventEarnings ReleaseMay 1, 2026Filing
  • 8-K eventPhase 2 Study AnnouncementApr 29, 2026Filing

Questions

Frequently asked questions

What is Tonix Pharmaceuticals Holding Corp.'s market cap?

Tonix Pharmaceuticals Holding Corp. (TNXP) has a market capitalization of $198M.

What is TNXP's P/E ratio?

A meaningful P/E ratio is not available for TNXP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is TNXP's price-to-book (P/B) ratio?

TNXP trades at 0.81 times book value per share.

Are insiders buying TNXP stock?

SEC Form 4 filings show no open-market insider buys at Tonix Pharmaceuticals Holding Corp. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

CHRS

Coherus Oncology, Inc.

$198.7M

ARTV

Artiva Biotherapeutics, Inc.

$193.8M

IPSC

Century Therapeutics, Inc.

$205.2M

SRZN

Surrozen, Inc.

$184.8M

RNAC

Cartesian Therapeutics, Inc.

$212.4M

NBP

NovaBridge Biosciences

$213.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.